Tear proteins are potential biomarkers, drug targets, and even biotherapeutics. As a biotherapeutic, a recombinant tear protein might physiologically rescue the ocular surface when a deficiency is detected. Such a strategy pays more attention to the natural prosecretory and protective properties of the tear film and seeks to alleviate symptoms by addressing cause, rather than the current palliative, non-specific and temporary approaches. Only a handful of tear proteins appear to be selectively downregulated in dry eye, the most common eye disease. Lacritin and lipocalin-1 are two tear proteins selectively deficient in dry eye. Both proteins influence ocular surface health. Lacritin is a prosecretory mitogen that promotes basal tearing when applied topically. Levels of active monomeric lacritin are negatively regulated by tear tissue transglutaminase, whose expression is elevated in dry eye with ocular surface inflammation. Lipocalin-1 is the master lipid sponge of the ocular surface, without which residual lipids could interfere with epithelial wetting. It also is a carrier for vitamins and steroid hormones, and is a key endonuclease. Accumulation of DNA in tears is thought to be proinflammatory. Functions of these and other tear proteins may be influenced by protein-protein interactions. Here we discuss new advances in lacritin biology and provide an overview on lipocalin-1, and newly identified members of the tear proteome.
Introduction
Tears accumulate on the avascular corneal epithelium, and vascularized conjunctiva, as a translucent film rich in proteins, lipids and metabolites. The tear proteome is estimated to comprise 1,543 proteins (Zhou et al., 2012) , with over half designated as 'intracellular' (Table 1) by Gene Ontology, implying that cell death from normal epithelial renewal may be a contributor. Beyond its capacity to lubricate the lid, tears are essential for the refraction of light (Montés-Micó et al., 2007) . Equally important and irreplaceable by drugs or drops is the role of tears in promoting corneal epithelial health for when tears are chronically insufficient the epithelium becomes stressed and releases inflammatory cytokines that further exacerbate the situation (Massingale et al., 2009) . Dry eye affects 5 -6% of the general population, rising to 6 -9.8% and as high as 34%, respectively in postmenopausal women (Schaumberg et al., 2003) and the elderly (Lin et al., 2005) .
Relatively few tear proteins appear to be selectively down-or upregulated in dry eye (Table  1) . Appreciating which are bioactive and at what molar levels would be insightful. The only growth factor-like molecule downregulated in mild to severe aqueous deficiency was lacritin (Srinivasan et al., 2012) . Lacritin promotes basal tearing when added topically in rabbits (Samudre et al., 2011) . Also decreased was lipocalin-1 (Srinivasan et al., 2012) , that cleanses the ocular surface of lipids that would otherwise interfere with ocular surface wetting (Glasgow and Gasymov, 2011) . Lacritin was the most severely downregulated protein in contact lens-related dry eye (Nichols and Green-Church, 2009 ) -perhaps in part because it is readily adsorbed on contact lenses . It is also deficient in blepharitis (Koo et al., 2005) , a common inflammation of the eyelid, associated with evaporative dry eye (Mathers et al., 1993) . Two studies did not note any lacritin change in dry eye using mass spectrometry coupled with liquid chromatographic cationic separation followed by reverse phase separation (Zhou et al., 2009; Boehm et al., 2013) , although one observed a decrease of lipocalin-1 (Zhou et al., 2009 ). 2-D SDS PAGE prior to mass spectrometry (Koo et al., 2005; Nichols and Green-Church, 2009; Srinivasan et al., 2012 ) is necessary to distinguish monomeric lacritin from inactive multimeric lacritin (Velez et al., 2013) , and likely also the inactive lacritin-c splice variant (McKown et al., 2009) . Exploration of lacritin cell targeting and signaling mechanisms has revealed a network of interdependent molecules, each necessary for lacritin activity. New evidence is suggesting that some of these are also decreased in dry eye. Here we review recent advances in our understanding of lacritin, and provide an overview of lipocalin-1 whose eye specific expression parallels that of lacritin. We also update our current understanding of the tear proteome.
Lacritin

Structure and expression
The discovery of lacritin indirectly emerged from a screen for novel factors capable of promoting tear protein secretion, with cDNA cloning out of a human lacrimal gland library (Sanghi et al., 2001) . The lacritin gene, LACRT, is one of the most eye specific (Sanghi et al., 2001 ) and resides on 12q13, within ~1.24 Mb of the AAAS gene associated with alacrima (Kumar et al., 2002) . Human lacritin is coded by a 417 bp open reading frame that translates as a 14.3 kDa hydrophilic protein with a 19 amino acid signal peptide resulting in a secreted protein with a predicted molecular mass of 12.3 kDa (Fig. 1) . Mobility in SDS PAGE gels is ~18 kDa for recombinant lacritin generated in E. coli (Wang et al., 2006) , and 23 -25 kDa with glycosylation in tears (Seifert et al., 2012) . Such aberrant mobility may be attributable to lacritin's C-terminal amphipathic -helix that supports lacritin cell surface targeting of the heparan sulfate proteoglycan syndecan-1 (Fig. 1) , as confirmed by circular dichroism (Wang et al., 2006; Zhang et al., 2013) and point mutagenesis . Lacking the C-terminal amphipathic -helix and inactive ) is splice variant lacritin-c (McKown et al., 2009) . PSIPRED (v3. 3) predicts three other C-terminal half -helices ( Fig. 1 ) in secreted lacritin. The C-terminal half is thus ordered, whereas the N-terminal half is largely diisordered (Fig. 1; McKown et al, '09) . Thirteen sites of Oglycosylation (NetOGlyc 3.1) and one N-glycosylation site (NetNGlyc 1.0) are predicted (McKown et al., 2009) , with O-glycosylation restricted to the disordered region predicted by PONDR ('Predictor of Naturally Disordered Regions') in the N-terminal half (McKown et al., 2009) . The N-glycosylation site flanks the syndecan-1 binding domain, but is not generally conserved among orthologs. Patients with climatic droplet keratopathy display decreased N-linked glycosylation (Lei et al., 2009) , however non-glycosylated lacritin is active in prosecretory, mitogenic, cytoprotective and syndecan-1 binding assays. It is possible that glycosylation enhances stability.
Lacritin mRNA and protein are highly expressed in human lacrimal gland as the sixth most common mRNA (Ozylidirim et al., 2005) , with detection in lacrimal acinar cell secretory granules (Sanghi et al., 2001) . Lacritin protein also appears to be expressed by the human meibomian gland (Tsai et al., 2006) , and was recently detected in the gland of Wolfring (Ubels et al., 2012) . In monkey, lacritin mRNA has been detected also in conjunctiva and corneal epithelium, and at low levels in other eye tissues including retinal and lens epithelia (Nakajima et al., 2007) . A single retinal hit has been noted in Human Proteinpedia (HuPA_00710). In non-ocular tissues, lacritin is highly expressed in an apparent ductal-like cell in human submandibular and parotid glands -but not in acinar cells. Lacritin also appears to be produced at low levels in thyroid (Sanghi et al., 2001) , and has been noted by RT-PCR in normal breast and invasive breast cancer tumors (Weigelt et al., 2003) and by proteomics in saliva (Human Proteinpedia [HuPA_00047] ), lung lavage (HuPA_00022) and plasma (Schenk et al., 2008) . No other expressing tissues were noted in a fifty tissue RNA dot blot and by tissue microarray of seventy-five different human organs (Sanghi et al., 2001) . Release is apical from acinar cells into ducts that carry lacritin onto the surface of the eye (Morimoto-Tochigi et al., 2010) , where lacritin is detected in tears (Sanghi et al., 2001; Nakajima et al., 2007; Seifert et al., 2012) .
Predicted and demonstrated orthologs
We extracted LACRT aligned genomic sequences from over twenty-one species in Ensembl (release 70), guided by AceView defined exon boundaries for LACRT (Supplementary Fig.  1 ; see method in Laurie et al., 2012) . Exon sequences were spliced ( Supplementary Fig. 2 ) and then translated ( Supplementary Fig. 3 ), with some displaying incomplete sequence. No complete mouse or rat ortholog was apparent although other rodents are represented, an observation possibly related to the predicted telomeric location or alternatively reflective of significant differences in lacrimal specific gene expression between mouse and human (Ozyildirim et al., 2005) . Non-primate lacritins display on average 25% amino acid identity with human lacritin (vs 75% for primates), although bushbaby lacritin is only 41% identical (Table 2 ). Analysis of each by PSIPRED (version 3.3) displayed a predominance of predicted -helices in the C-terminal half (Fig. 2) .
Predicted identity of horse lacritin with human lacritin (45%) is greater than any other known non-primate ortholog (Table 2) . Blotting of horse tears with anti-C vs anti-N terminal domain specific antibodies revealed that horse lacritin was mainly represented as a ~13 kDa C-terminal-half fragment with a predicted amphipathic helix at the C-terminus .
Tools and manufacture
The 363 bp coding region without signal peptide coding sequence of human lacritin was subcloned into pTYB1 (New England Biolabs, Inc; Ipswich MA) as 'pLAC' for expression of lacritin-intein fusion protein (Wang et al., 2006) . Intein serves as a convenient affinity tag for purification that is retained on the chitin affinity column upon elution withmercaptoethanol. Eluted lacritin is concentrated, dialyzed versus PBS and then is further purified on DEAE (diethylaminoethanol) covalently linked to Sepharose. DEAE removes contaminating endotoxin. Also binding to DEAE is a C-terminal lacritin cleavage fragment, and the E. coli chaperone DnaK . DnaK is likely involved in lacritin synthesis.
Although lacritin's low nanomolar prosecretory (Sanghi et al., 2001) , mitogenic (Wang et al., 2006) and cytoprotective ) activities require only 1 or 10 nM lacritin, optimizing production from current ~0.1 g/l yields is desirable for cost efficiencyparticularly for scale up. C-terminal hydrophobic residues might promote some misfolding. Misfolded molecules aggregate and become secluded in inclusion bodies. Single or double point mutagenesis to serine of I68, I68/I78, V69, I73, V91, I98, F104, L108, L109 or F112 enhanced yields two or three times that of unaltered lacritin . Some are inactivating, but lacritins V69S, I73S, L108S and L109S retain activity . Salt bridges can also promote misfolding, although many are stabilizing. We mutated several. Increases in yield were noted, particularly with lacritins K66S/E70S, K66S/E70S/ E103S/K107S and E103S/K107S , of which lacritin K66S/E70S retains activity. Another approach is to address codon usage. Some common human codons are rare or uncommon in E. coli such that tRNA's necessary for recombinant protein production are insufficient. Thirteen synonymous mutants were generated, however yield increases were low. It is possible that rare to common codon mutagenesis of lacritins V69S, I73S, L108S, L109S or K66S/E70S may increase yields .
Cell targeting
A deglycanated form of syndecan-1 was discovered to be the main cell surface binding protein for lacritin by mass spectrometric sequencing cell surface proteins bound to lacritin columns in buffer containing 100 mM NaCl. Validation was by affinity precipitation . Syndecan-1 is a widely expressed cell surface heparan sulfate proteoglycan with a carboxy terminal end anchored in the plasma membrane with short cytoplasmic tail, and an ectodomain substituted proximally with chondroitin sulfate chain(s) at serines 184 and 194 (human syndecan-1; numbering excludes the signal peptide), and distally with up to three heparan sulfate chains (serines 15, 23, 25) without or with a short chondroitin sulfate chain (Kokenyesi and Bernfield, 1994 ). Lacritin's C-terminal -helix (Wang et al., 2006) bound a domain within syndecan-1 amino acids 1 -50, with binding dependent on prior heparanase cleavage of heparan sulfate . SiRNA knockdown of syndecan-1 abrogated lacritin dependent mitogenic activity, as did depletion of heparanase (but not heparanase-2), but could be rescued by addition of exogenous heparanase or with bacterial heparitinase . Recently, we narrowed the binding domain to hydrophobic amino acids 20 -30 that when reduced to synthetic peptide GAGAL enhanced lacritin C-terminal -helicity . Binding is equally dependent on substitution of S23 and S25 (and possibly S15) with both heparan sulfate and chondroitin sulfate as a novel hybrid domain of hydrophobic core protein, heparanase cleaved heparan sulfate and adjacent chondroitin sulfate . Heparanase is not widely expressed, but is detected in tears by Western blotting (Ma, Wang and Laurie, unpublished) , although at levels too low yet for proteomic detection.
With each modification essential for lacritin binding, cell targeting by lacritin is very selective. Contributing to cell selectivity is a signaling receptor(s). Signaling is initiated within seconds (Wang et al, 2006) . A candidate G-protein coupled receptor has been identified (Zimmerman and Laurie, unpublished) . SiRNA knockdown in cells abrogates lacritin dependent mitogenesis (Ma and Laurie, unpublished) . Lacritin targets rat (Sanghi et al., 2001 ) and monkey (Fujii et al., 2013) primary lacrimal acinar cells in secretion assays, and primary human corneal epithelial and HCE-T (Wang et al., 2006 human corneal epithelial (SV40-large T) cells in cytoprotection assays. Lacritin is mitogenic for HCE-T, HCE, human salivary HSG/HeLa and embryonic kidney (HEK293) cells, but not for human epidermal (A431), cervical (HeLa), foreskin fibroblast (HS68), fibrosarcoma (HT1080), erythroleukemia (K-562), breast carcinoma (MCF7), melanoma (SK-MEL, WM-164), Leydig (TM4), Sertoli (TM3), glioma (U-1242-MG, U251-MG) and mouse fibroblast (NIH3T3) (Wang et al., 2006) . No fibrosis, angiogenesis, or inflammation has been observed in eyes of lacritin treated rabbits (Samudre et al., 2011) , monkeys or rats (unpublished).
Prosecretory and protearing activities
Our original discovery screen employed primary cultures of rat lacrimal acinar cells (Sanghi et al., 2001 ) in a 96-well assay that monitored tear peroxidase release normalized to cellular DNA (Chen et al., 1998) . 0.8 -13 nM of recombinant human lacritin stimulated peroxidase secretion in a dose-dependent manner, without affecting carbachol/VIP stimulated secretion (Sanghi et al., 2001) . Similarly, lacritin purified from monkey tears triggered protein secretion from monkey lacrimal acinar cells even under conditions of stress from the inflammatory cytokines interferon-and tumor necrosis factor that abrogated carbachol stimulated secretion (Fuji et al., 2013) . Low level tear stimulation, induced in part by lacritin (Samudre et al, 2011) , is responsible for continually wetting the ocular surface (Dartt, 2009 ) with basal tears.
3.2 nM recombinant human lacritin triggers calcium signaling by cultured human corneal epithelial cells (Sanghi et al., 2001) . The corneal epithelium is intimately associated with sensory nerves that penetrate and form neuro/epithelial junctional complexes (Muller et al., 1996) . Treating normal rabbits with 0.8 -8 M recombinant lacritin promoted tearing within 60 min -the earliest time point assayed, and lasted at least 240 min (Samudre et al., 2011) . Tearing was measured via Schirmer strips 10 min after proparacaine anesthesia to minimize the inclusion of reflex tears. To test for toxicity, eyes were treated with 4 M lacritin three times daily for two weeks, or alternatively with 1.1 M lacritin truncation C-25 that lacks the syndecan-1 binding site. Lacritin steadily enhanced basal tearing without toxicity. One week after washout, basal tearing remained elevated, whereas C-25 had no effect (Samudre et al., 2011) . These observations highlight the potential of lacritin as a tear secretagogue alone or in combination with other agonists.
Promitogenic activity and signaling
Early studies also noted that recombinant lacritin promoted HSG/HeLa cell proliferation over a 0.2 -0.8 nM dose range that approximated the serum positive control (Sanghi et al., 2001) , suggesting that lacritin was a pleiotropic tear factor that might contribute to regulation of epithelial renewal as it flowed downstream from lacrimal acinar cells onto the eye (Wang et al., 2006) . Over a broader dose range, lacritin displayed a biphasic dose response with an optimum of 1 or 10 nM. Lacritin truncations lacking 15 -49 amino acids from the C-terminus were inactive, whereas truncation of 5 or 10 C-terminal, or 24 Nterminal amino acids had no effect (Wang et al., 2006) . Mitogenic signaling is initiated within seconds and proceeds through the G proteins G i or G o to the phosphatase PP2A (Karnati and Laurie, unpublished), leading to rapid dephosphorylation of PKC . Dephosphorylated protein kinase C-(PKC ) translocates to the perinuclear Golgi region where it activates phospholipase D1 (PLD1) and phospholipase C 2 (PLC 2) to generate IP3. IP3 triggered release of calcium into the cytoplasm activates the phosphatase calcineurin to in turn dephosphorylate the transcription factor NFATC1 (nuclear factor of activated T cells, calceneurin dependent 1) that translocates into the nucleus (Wang et al., 2006) to co-regulate the transcription of genes involved in cell growth and secretion (Heit et al., 2006) . Via a parallel pathway, G i or G o /PKC /PLC activates PLD1 and in tun mTOR that also promotes proliferation in a manner synergistic with NFATC1 (Wang et al., 2006) .
Cytoprotective activity
Lacritin promotes the survival of human corneal epithelial cells stressed with interferonand tumor necrosis factor . As a simple assay, we monitored the nuclear translocation of 'Forkhead box O3' (FOXO3). FOXO3 is nuclear in stressed or dying cells and cytoplasmic when cells are healthy. When interferon-/tumor necrosis factor stressed human corneal epithelial cells were treated 10 mM lacritin, FOXO was cytoplasmic -but remained nuclear with 10 nM C-25 . The same assay monitored manipulations with normal and dry eye tears. Normal, but not dry eye, tears are protective (cytoplasmic FOXO3), however protective activity is lost when lacritin is completely immunodepleted from tears (nuclear FOXO3). Similarly, spiking 10 nM lacritin, but not C-25, into dry eye tears restores protective activity .
To begin to discern how lacritin is prosurvival, we monitored the cleavage of caspases 3 and 9 in the absence or presence of lacritin. Lacritin had no effect on caspase cleavage and no DNA fragmentation was apparent, suggesting that interferon-/tumor necrosis factor treatment to induce stress did not trigger apoptosis and that the lacritin survival mechanism is not anti-apoptotic. However changes were observed in the lipidation of autophagy marker microtubule-associated protein 1 light chain 3 (LC3) . Autophagy removes stress damaged proteins and organelles from cells by enclosure and capture in lipidated LC3 covered autophagosomes. We monitored the process by transducing interferon-/tumor necrosis factor stressed human corneal epithelial cells with an LC3 construct double tagged with low pH sensitive green fluorescent protein and pH insensitive mCherry ('LC3RG') such that time dependent transition of LC3RG isolation membranes (double membrane that begins the enclosure of damaged proteins or organelles) to autophagosomes (enclosure completed and fused) and then fusion with lysosomes (low pH) could be followed. We discovered that lacritin, but not C-25, promoted the acceleration of autophagy for ~60 min, and then ceased. This was sufficient to restore oxidative phosphorylation, promote both mitochondrial fusion and cell survival, and trigger changes in 29 metabolites, including the suppression of kynurenine . Kynurenine is elevated in sera of patients with primary Sjögren's syndrome (Pertovaara et al., 2005) , rheumatoid arthritis and other autoimmune diseases (Katz et al., 2008) . When instead of interferon-/tumor necrosis factor stress, LC3RG cells were co-transduced with a cyan fluorescent protein-labeled huntingtin construct (Htt103Q) that is cell toxic, the same autophagic pulse was triggered by lacritin, but not C-25. No autophagic pulse was apparent when cells were co-transduced with a non-toxic huntingtin construct (Htt25Q) . Thus stress is a prerequisite for lacritin stimulated autophagy.
Unlike mitogenic signaling, survival signaling is mediated by FOXO3 and FOXO1. By 1 min, lacritin promotes the acetylation (and phosphorylation) of FOXO3 -a modification coincident with ligation of autophagy-related protein 101 and acceleration of autophagy . We also observed that stress promotes the immediate acetylation of FOXO1, as first reported by Zhao et al., (2010) in cancer cells, but unlike Zhao et al., (2010) , stress was insufficient to promote ligation of acetylated FOXO1 with autophagyrelated protein 7. Instead, lacritin is required and does so 5 -15 min after administration . The autophagic pulse mechanism appears to be well-suited for the stressed ocular surface as each new bolus of lacritin is delivered to the eye, to then drain away into the nasolacrimal duct. Maintaining all elements of this system may be required for ocular surface health.
Molar levels in tears
Systematically discerning the bioactivity and molar variation of individual tear proteins in the entire tear proteome could open up a new era of ocular diagnosis and treatment. To gain information on lacritin levels in tears, a 'lacritin' ELISA sold by USCN (#E2576Hu, L091229053) was tested. Unfortunately, it failed to detect recombinant human lacritin and the positive control migrated in SDS-PAGE as a broad smear (McKown and Laurie, unpublished) . We therefore established an ELISA with N-terminal-specific anti-lacritin antibody 'anti-Pep Lac N-Term' that detects lacritin in tears without interference from other tear proteins (Seifert et al., 2012) . Basal tear samples from 66 individuals aged 18 -52 years were individually tested over six replicates revealing a mean of 4.2 ± 1.17 ng/100 ng of total tear protein with little difference by gender, although lacritin may be greater in female reflex tears (Ananthi et al., 2011) . Assuming an estimated basal tear protein concentration of ~8 mg/ml (Sitaramamma et al., 1998) , lacritin molar levels are 18 -27 M. In contrast, lysozyme is ~20 ng/100 ng total tear protein (Seifert et al., 2012) , or ~100 M -in agreement with others (Sen and Sain, 1982 [80 M] , Velos et al., 1985 [86 M] ) with estimates to 300 M (Eylan et al., 1977) . To assess whether time of day influences lacritin levels, we collected tears from 34 additional individuals at 7:30 -8:30 am (0 hr), 11:30 am -12:30 pm (4 hr), 4:30 -5:30 pm (8 hr) and 7:30 -8:30 am the following day (24 hr). No differences were observed.
18 -27 M lacritin is more than one-thousand fold greater than the accepted dose optimum of 1 -10 nM (Wang et al., 2006) , although 0.8 -8 M was effective when applied topically in rabbits (Samudre et al., 2011) . Perhaps the availability of epithelial bioactive lacritin is restricted by an unknown ocular surface or secretory mechanism. Present in all anti-lacritin tear blots was the ~25 kDa lacritin band, and a ~13 kDa fragment. Also present, but overlooked were ~50 kDa, ~75 kDa and occasionally even higher molecular weight bands. Secondary antibodies showed nor cross-reactivity with tears. With new anti-lacritin monoclonal antibody 1F5 displaying preference for the 75 kDa band, we explored the putatively larger species in more detail (Velez et al., 2013) and discovered that tissue transglutaminase in tears (Table 1) generates lacritin multimers. Multimers are largely inactive (Velez et al., 2013) .
Exogenous tissue transglutaminase (1.5 M) from guinea pig promoted crosslinking between deprotonated lacritin lysines 82 or 85 with acceptor glutamine 106 that was initiated within 1 min, and completed 40 -90 min later. No crosslinking was observed in the presence of EDTA, or after prior denaturation of tissue transglutaminase by boiling, or when tissue transglutaminase was replaced by an inactive recombinant human tissue transglutaminase (Velez et al., 2013) . We then immunodepleted all lacritin monomer, multimer and fragment from human tears. Recombinant lacritin spiked into immunodepleted tears formed dimers, trimers and tetramers after overnight incubation at 37°C. In the negative control without tears, a small amount of dimer formed (Velez et al., 2013) . Since glutamine 106 resides within the lacritin mitogenic domain (amino acids 100 -109) that targets syndecan-1, we wondered whether lacritin activity was affected by cross-linking, and discovered that syndecan-1 binding was substantially decreased. Also suppressed was lacritin cytoprotective activity (Velez et al., 2013 ) since tissue transglutaminase cross-linked lacritin was substantially less effective at rescuing interferon-/tumor necrosis factor stressed human corneal epithelial cells. Blotting suggests that normal human tears contain 0.6 M tissue transglutaminase, that thus appears to act as a negative regulator of monomeric (epithelially active) lacritin. Primary human corneal epithelial cells express both transglutaminase 1 and tissue transglutaminase mRNAs. mRNA expression of both increases with hyperosmolar stress, particularly transglutaminase 1 (Chen et al., 2008) , however transglutaminase 1 has not been detected in tears. Thus, lacritin may be subjected to enhanced cross-linking and deactivation in dry eye.
3. Lipocalin-1
Structure and expression
Tear lipocalin (LCN1; recently reviewed by Glasgow BJ and Gasymov, 2011; Dartt, 2011) was originally noted as an unknown band in early electrophoretic separations of human tears and named tear pre-albumin (Erickson et al., 1956 ), based on its paper electrophoretic mobility near serum albumin proximal to the anode. Lack of immunological cross-reactivity in normal human tears suggested that the two were distinct (Josephson and Lockwood, 1964) , in keeping with earlier studies by Fleming suggesting lack of serum immunoreactivity by rabbit anti-human tear antibodies (Fleming and Allison, 1925) . Others confirmed this observation by gel electrophoresis, immunabsorption, gel fractionation and analytical ultracentrifugation, that also distinguished the substantially differing molecular weights of the two (Bonavida et al., 1969) . In 1987, Pervaiz and Brew proposed the family name 'lipocalin' to describe a secondary or tertiary structurally homologous group of proteins with affinity for lipophilic ligands (Pervaiz and Brew, 1987) . Subsequent cDNA cloning (Redl et al., 1992) from N-terminal tear albumin protein sequence out of a human lacrimal gland cDNA library identified a further member of the lipocalin family that was 58% identical to von Ebner's gland protein from rat, and identical to human von Ebner's gland protein, and was later designated as tear lipocalin with gene symbol LCN1. Tear lipocalin is a prominent component of tears with an estimated concentration of ~75 M (Fullard et al., 1991) .
Tear lipocalin runs as a ~18 kDa band in SDS PAGE (Millar et al., 2009) . O-linked glysylation of C-terminal residues threonine 170 and serines 172 and 175 is weakly predicted by NetOGlyc 3.1 (numbering includes signal peptide). No N-linked glycosylation sites are predicted (NetNGlyc 1.0). Tear lipocaln forms an eight stranded antiparallel barrel structure with C-terminal -helix that creates a ~15 Å deep central cavity with positively charged bottom surface for ligand binding. Hydrophobic residues line the cavity (Gasymov et al., 2001; Breusted et al., 2005) , that best accommodates fatty acids of 18 (22.5 Å) to 24 carbons . The disulphide bond between cysteines 79 and 171 restricts retinol binding in preference to native lipids (Glasgow et al., 1998) . Tear lipocalin also binds lysozyme and lactoferrin through electrostatic interactions , in keeping with the possibility that the three might be co-secreted as a complex.
Like LACRT, LCN1 is one of the most highly expressed human lacrimal gland genes and is equally eye specific (Ozyildirim et al., 2005) . Western blotting has detected tear lipocalin in tears, saliva, sweat, and nasal mucus (Redl et al., 1992) . Some expression in other tissues has been observed, including lung (Redl et al., 1998) , pituitary gland (Wojnar et al., 2002) , prostate (Holzfeind et al., 1996) , plasma (Schenk et al., 2008) and semen (Pilch and Mann, 2006) .
Orthologs
Twenty-eight tear non-overlapping orthologs are currently listed by Ensembl (release 70). Sequence identity of human tear lipocalin with primate and non-primate tear lipocalins is respectively 82 and 44%.
Tools and manufacture
Recombinant tear lipocalin has been largely produced in E. coli, although mammalian recombinant protein is commercially available. A large collection of point mutated tear lipocalins have been generated by the Glasgow group for structural studies (for example, Gasymov et al., 2002) .
Lipid binding activity
Tear lipocalin is the main lipid binding protein in tears (Glasgow et al., 1995) . It copurifies out of human tears with stearic (5.9 M), palmitic (4.4 M) and lauric (0.4 M) acidslevels in keeping with the relative affinities of each for tear lipocalin as determined by displacement of the fatty acid analog DAUDA . By scavenging lipids, tear lipocalin is thought to help clear the ocular surface of sloughed cellular debris from epithelial turnover that might interfere with wetting. It also stabilizes the tear film (Schoenwald et al., 1998) , and with ligand is itself stabilized (Tsukamoto et al., 2009 ).
Clearance of lipids coupled to tear lipocalin
Cell surface 'lipocalin-1 interacting membrane receptor' (LBR1L) captures tear lipocalin for endocytosis. Endocytic internalization of FITC-labeled tear lipocalin (Wojnar et al., 2003) or -lactoglobulin (Fluckinger et al., 2008) in NT2 neuronal cells was abrogated by antisense knockdown of LMBR1L. LMBR1L is a plasma membrane protein with nine predicted transmembrane domains (Wojnar et al., 2001) , discovered in a phage display screen of tear lipocalin binding proteins (Wojnar et al., 2001) . LMBR1L is widely expressed, but is not listed in corneal or lacrimal gland EST databases (NEIBank) suggesting either that it is absent, or more likely that expression is low (as is common for receptor proteins).
Cysteine protease inhibition activity
Recombinant tear lipocalin (5 -10 M) and tear lipocalin synthetic peptide (50 -150 M) inhibited papain activity with similar activity as cystatin C (CST3), indicating that tear lipocalin is a cysteine protease inhibitor (van't Hof et al., 1997). Tear lipocalin contains amino acid motifs similar to papain binding domains of family 2 cystatins. Leucine residues in the first cystatin like motif are necessary for protease inhibitor activity (Wojnar et al., 2001 ).
Bacterial growth inhibitory activity
Tear lipocalin (5 M) inhibits the growth of E. coli in an FeCl 3 reversible manner by capturing secreted bacterial siderphores with an affinity similar to stearic acid -suggesting that it is physiologically relevant. Growth assays were performed in M9 minimal medium with a NaCl concentration of 10 mM (Fluckinger et al., 2004) . Siderphores deliver extracellular iron necessary for bacterial growth in minimal medium.
Endonuclease activity
Homology of two tear lipocalin sequence motifs with an Mg 2+ dependent endonuclease from gram negative Serratia marcescens was rationale for studies demonstrating that tear lipocalin displays endonuclease activity, although 1355 fold less active than DNase I . Human reflex tears contain 714 ng/ml DNA, and endonuclease activity. The activity largely co-fractionates with tear lipocalin, and is Mg 2+ dependent and partially NaCl sensitive (Yusifov et al., 2008) . Strands of DNA of increased length in dry eye tears have been detected on Schirmer strips, coincident with inflammation, and decreased tear nuclease activity -the latter thought to be contributed by tear lipocalin and DNase I (Sonawane et al., 2012) .
New additions to the tear proteome
We previously assembled all tear proteomic data into a single table, restricting entry to proteins designated as 'extracellular' or 'plasma membrane' in their primary or alternative location (Laurie et al., 2008) . Now updated with 139 new entries from Zhou et al., (2012) , the additions supplement tears with proangiogenic, anti-angiogenic, retinal survival, epithelial repair, cysteine protease inhibitor, immunosuppressive, and immunostimulatory activities (Table 1) . Thirteen are highlighted below.
Angiogenesis
Exclusion of blood vessels from the cornea is essential for transparency (Ambati et al., 2006 ). Yet, tears contain both stimulators and inhibitors of angiogenesis. Now identified in tears are the stimulator angio-associated migratory cell protein (AAMP; 52 kDa) and the inhibitor fibulin 3 isoform 1 (EFEMP1; ~55 kDa). Antibody inhibition and antisense knockdown studies provide indirect evidence for the possibility that Angio-associated migratory cell protein is required for endothelial tube formation in co-culture with astrocytes (Beckner et al., 2002) . 0.2 -0.9 M recombinant fibulin 3 isoform 1 inhibits sprouting of endothelial cells grown on collagen gels (Albig et al., 2006) . Fibulin 3 isoform 1 binds the C-terminus of TIMP3 and, together with TIMP3, is a disease gene for macular degeneration (Klenotic et al., 2004) .
Growth-like factors and epithelial biology
Tears contain growth factors. New tear growth factors (Zhou et al., 2012) are granulin (GRN; also known as epithelin), hepatoma derived growth factor (HDGF) and platelet derived growth factor C (PDGFC). Precursor progranulin (88 kDa) is processed to granulin (epithelin) 1 and 2. 0.8 -3 nM granulin 1 enhances colony formation by normal rat kidney cells in agar in a manner that is opposed by 83 nM granulin 2 (Plowman et al., 1992) . Intraocular injection of 36 M hepatoma derived growth factor (~28 kDa) after ocular nerve excision in rats increases the survival of retinal ganglion cells -in part via PI3K-Akt and MAP kinase signaling (Hollander et al., 2012) .
Platelet derived growth factor C is secreted in inactive form in the vitreous, where it is activated by plasmin and thought to be involved in proliferative vitreoretinopathy (Lei et al., 2008) . Platelet derived growth factor C is mitogenic for fibroblasts over a dose range of 0.08 -0.8 nM (Li et al., 2000) .
Other interesting epithelial effectors now identified in tears include: trefoil factor 3 (TFF3; 7 -12 kDa), cystatin-M (CST6; ~16.5 kDa) and growth arrest specific 6 (GAS6; ~75 kDa). Trefoil factor 3 plays an important role in epithelial repair. It is upregulated in injured cornea, and promotes the healing of NaOH wounded mouse corneas over a 7 -400 M dose range (Paulsen et al., 2008) .
Cystatin-M is a cysteine protease inhibitor. Mice lacking cystatin-M develop metaplasia and keratitis of cornea (Zeeuwen et al., 2010) .
Recombinant growth arrest specific 6 promotes photoreceptor outer segment phagocytosis with a dose optimum of 100 nM over a biphasic dose response (Hall et al., 2001 ). Antigrowth arrest specific 6 antibodies inhibit phagocytosis by retinal pigment epithelial cells (Karl et al., 2008) .
Inflammation
Several new proteins are immunosuppressive (peptidylprolyl isomerise B [PPIB, also known as cyclophilin B], galectin 9 [LGALS9]), or immunostimulatory (pre B cell colony enhancing factor [NAMPT; also known as visfatin], arginase [ARG1]). Peptidylprolyl isomerise B (~24 kDa) binds cyclosporine A with high affinity (Kd of 9.8 nM; Husi et al., 1994) to together inhibit the phosphatase calcineurin within cells (Arber et al., 1992) .
Calcineurin is activated by calcium, as a downstream mediator of calcium signaling. Tear peptidylprolyl isomerise B would be expected to interact with topical cyclosporine A.
Galectin 9 (~40 kDa) is an S-type lectin with affinity for -galactosides. Galectin 9 (025 -0.75 M) binds HAVCR2 (Tim-3) via carbohydrate recognition domain residues R64 and R238 to promote the death of T H 1-, but not T H 2-, CD4 + and CD8 + T cells, since HAVCR2 is a T H 1-specific cell surface protein. Galectin 9 is therefore involved in T cell suppression making it a potential therapeutic candidate for treatment of autoimmune diseases (Zhu et al., 2005) .
Pre B cell colony enhancing factor (~56 kDa) is a proinflammatory adipokine. 9 -45 nM pre B cell colony enhancing factor promotes the production of cytokines by CD14(+) monocytes (Moschen et al., 2007) and by rheumatoid arthritis synovial fibroblasts (Meier et al., 2012) , including IL-6, TNF and IL1 .
Arginase (~35 kDa) is a manganese metalloenzyme that successfully competes for the substrate L-arginine with nitric oxide synthase, thereby reducing levels of immunoregulatory nitric oxide. Mice lacking arginase display little lipopolysaccharide induced uveitis ).
Innate defense
Tears contain the small leucine-rich keratan sulfate proteoglycan lumican (LUM; ~75 kDa), that is abundant in the cornea as a modulator of collagen fibril formation (Chakravarti et al., 1998) , and deficient in macular corneal dystrophy in mature form (Hassell et al., 1980) . P. aeruginosa infection in lumican null versus mice suggests that lumican contributes to the innate response and clearance of bacteria (Shao et al., 2013) .
Conclusions
Advantage should be taken of tear proteins as potential biomarkers, drug targets, and biotherapeutics. Tear-based biotherapeutics have considerable potential, particularly with the relatively small number of tear proteins that appear to be selectively downregulated in dry eye. Rather than simply alleviating symptoms, causes of ocular surface diseases may be addressable. Lacritin-and lipocalin-1-based therapeutics offer a platform to initiate this approach. Newly identified members of the tear proteome expand our appreciation of the functional capacity of the thin, but functionally dynamic tear film.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Linear diagram of secreted lacritin. PSIPRED (v3.3) predicted -helices are indicated by rectangles; the arrow indicates a short predicted -strand. The most C-terminal -helix is amphipathic and targets the cell surface proteoglycan syndecan-1 after heparanase modification (Wang et al., 2006) . Both the hydrophobic face (L108/L109/F112) and the cationic face (Q103/K107 and K111) of lacritin are involved . These target three syndecan-1 elements : (i) the conserved hydrophobic sequence GAGAL, and (ii) chondroitin-4-sulfated and (iii) heparanase-cleaved 3-O-sulfated heparan sulfated chains on N-terminal serines 15, 23 and 25 (human syndecan-1 numbering excludes the signal peptide). -helicity of lacritin's C-terminal a-helix has been validated by circular dichroism (Wang et al., 2006; Zhang et al., '13) . Syndecan-1 has a short transmembrane domain known only for cytoskeletal signaling. Rapid lacritin signaling appears to be attributable to an associated G-protein coupled receptor, as first implied by pertussis toxin inhibitable mitogenic signaling (Wang et al., 2006) . Predicted and demonstrated lacritin orthologs. Shown are secondary structure predictions by PSIPRED (v3.3). Rectangles and arrow respectively indicate predicted -helices and astrand. The N-terminal -helix is the signal peptide. The most C-terminal -helix in human lacritin regulates many of lacritin's activities via an amphipathic structure. The list is derived from published reflex tear (1, 4), closed eye tear (2), open and closed eye tear (3), Meibomian gland secretion (14), open and closed eye tear capture ELISA or antibody array (5, 6) and lacrimal gland EST (7) analyses. Not listed are the numerous cytoplasmic proteins that are also detected in tears (2, 4).
*, , †,$,#,€,£,¥, § suggested to be less or more than normal in tears from patients suffering from *blepharitis (8), $#€ dry eye (9, 10,11), Sjögren's syndrome(12), †contact lens related dry eye (13) £climatic droplet keratopathy (15), ¥fusarium keratitis (16) or §dry eye and meibomian gland dysfunction (17).
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